In the future, we will evaluate the potential of PgP as a GCV and pHSV-TK co-delivery carrier to improve the bioavailability and half-life of GCV as well as increase the survival rate after treatment of PgP/pHSV-TK with PgP-GCV in rat T5 spinal cord tumor model. Here, PGP is linked to spinal cord neoplasm.